EMEA-002023-PIP01-16-M03

Key facts

Active substance
Avacopan
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0360/2019
PIP number
EMEA-002023-PIP01-16-M03
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral solid dosage form
  • Age-appropriate oral liquid dosage form
Condition(s) / indication(s)
Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Route(s) of administration
Oral use
Contact for public enquiries
ChemoCentryx Ireland Ltd.

Tel.  +1 6502102900
E-mail: regulatory@chemocentryx.com

Decision type
RPM: decision refers to a refusal on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating